CIK 0000021665 · Large accelerated filer
COLGATE PALMOLIVE CO
Sign in to watch- Ticker
- CL
- Exchange
- NYSE
- Industry
- Perfumes, Cosmetics & Other Toilet Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 131815595
- Phone
- 2123102000
- Business address
- 300 PARK AVE, NEW YORK, NY, 10022
- Former names
- COLGATE PALMOLIVE CO
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $8,027,828
- in 6 filings
Net −$8,027,828. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Tsourapas Panagiotis −$2.9M COO, CD, EMEA, APac, Skin sold 77% of stake
- Hazlin John −$2.3M Chief Growth Officer sold 46% of stake
- Wallace Noel R. −$2.0M Chairman, President & CEO sold 5% of stake
- NORRINGTON LORRIE M −$414K Director sold 9% of stake
- Malcolm Gregory −$402K EVP and Controller sold 29% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | Malcolm Gregory EVP and Controller | Sale | −4,100 | $97.97 | $402K | 10,061 |
| 2026-11-05 | NORRINGTON LORRIE M Director | Option exercise | +4,170 | $71.56 | $298K | 47,553 |
| 2026-11-05 | NORRINGTON LORRIE M Director | Sale | −4,170 | $99.31 | $414K | 43,383 |
| 2026-11-05 | NORRINGTON LORRIE M Director | Option exercise · Stock Option (Right to Buy) | −4,170 | 0 | ||
| 2026-11-05 | Wallace Noel R. Chairman, President & CEO | Sale | −20,000 | $100.26 | $2.0M | 359,700 |
| 2026-11-04 | Tsourapas Panagiotis COO, CD, EMEA, APac, Skin | Option exercise | +19,938 | $76.41 | $1.5M | 29,049 |
| 2026-11-04 | Tsourapas Panagiotis COO, CD, EMEA, APac, Skin | Sale | −19,938 | $98.74 | $2.0M | 9,111 |
| 2026-11-04 | Tsourapas Panagiotis COO, CD, EMEA, APac, Skin | Option exercise · Stock Option (Right to Buy) | −19,938 | 0 | ||
| 2026-11-04 | Hazlin John Chief Growth Officer | Option exercise | +23,376 | $77.04 | $1.8M | 50,397 |
| 2026-11-04 | Hazlin John Chief Growth Officer | Sale | −23,376 | $99.15 | $2.3M | 27,021 |
| 2026-11-04 | Hazlin John Chief Growth Officer | Option exercise · Stock Option (Right to Buy) | −23,376 | 0 | ||
| 2026-10-01 | NORRINGTON LORRIE M Director | Grant or award | +300 | $87.42 | $26K | 43,310 |
| 2026-10-01 | Newman Brian Director | Grant or award | +214 | $87.42 | $19K | 8,058 |
| 2026-10-01 | BILBREY JOHN P Director | Grant or award | +271 | $87.42 | $24K | 40,725 |
| 2026-09-16 | Wallace Noel R. Chairman, President & CEO | Grant or award | +29,649 | 379,700 | ||
| 2026-09-16 | Wallace Noel R. Chairman, President & CEO | Grant or award · Stock Option (Right to Buy) | +205,197 | 205,197 | ||
| 2026-09-16 | GRANT SHANE COO, Americas | Grant or award | +7,355 | 79,503 | ||
| 2026-09-16 | GRANT SHANE COO, Americas | Grant or award · Stock Option (Right to Buy) | +50,902 | 50,902 | ||
| 2026-09-16 | Tsourapas Panagiotis COO, CD, EMEA, APac, Skin | Grant or award | +4,597 | 11,447 | ||
| 2026-09-16 | Tsourapas Panagiotis COO, CD, EMEA, APac, Skin | Grant or award · Stock Option (Right to Buy) | +31,814 | 31,814 |
Page 1 of 10 · 193 trades